Gasami Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-01-12.
Gasami Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on January 12, 2026. The filing reports $20K sold. Its industry group is Biotechnology. It names Sarah Hunter-Chang (Executive Officer) (SEC Form D, January 12, 2026).
Sell to companies like Gasami Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-01-12 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Gasami Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Gasami Therapeutics, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Gasami Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Gasami Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Gasami Therapeutics, Inc. →Get the full cited report on Gasami Therapeutics, Inc.
What the filing shows about Gasami Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Gasami Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Gasami Therapeutics, Inc. See pricing
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $20K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Hope to pay executive officer wages from combination of grants and investments, but not sure yet how much we will get from what source.
Sarah Hunter-Chang is named as Executive Officer on the Form D that Gasami Therapeutics, Inc. filed with the SEC on 12 January 2026, the only person that filing names.
1 person named on the filing — 1 holding an executive role.
Named as of the 2026-01-12 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about Gasami Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Gasami Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Gasami Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Gasami Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Gasami Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Gasami Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/gasami-therapeutics-inc-form-d-26000001